Evolus, Inc.
$6.17
-2.3%Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -8.3).
Valuation inputs: P/E -8.3, earnings yield N/A, momentum -2.3%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE +2.2%, ROIC -24.6%).
Profitability stack: net margin -17.4%, ROE +2.2%, ROIC -24.6%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +110.2%, momentum -2.3%, net margin -17.4%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Evolus, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Evolus, Inc. Fair Value Envelope
Evolus, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Evolus, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Evolus, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Evolus, Inc. Street Expectations Map
Wall Street analysts project that EOLS stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 15.00, with estimates ranging from a low of 13.00 to a high of 17.00.
The consensus 1-year price target stands at 15.00, with estimates ranging from a low of 13.00 to a high of 17.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Evolus, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.48M and sold $2.21M worth of EOLS shares, resulting in $730K of net selling activity.
3 Months
0
0.00
163.5K
796.93K
-797K
-$797K
3-6 Months
0
0.00
12.8K
91.53K
-92K
-$92K
6-9 Months
143.4K
1.09M
0
0.00
+1.1M
+$1.09M
9-12 Months
50.0K
393.49K
133.6K
1.33M
-933K
-$933K
Top Buyers
Mitchell Tatjana
Officer: Chief Financial Officer
$1.09M
Stewart Brady
Director
$204K
White Albert G Iii
Director
$189K
Top Sellers
Moatazedi David
Director, Officer: See Remarks
$1.99M
Avelar Rui
Officer: See Remarks
$178K
Yamagishi-Dressler Tomoko
Officer: Chief Marketing Officer
$43K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $730K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider buyers and 3 sellers. Equal participation suggests mixed or neutral insider views.
No Dividend Yield Data
EOLS has not reported any dividend yield values in the available annual periods.
eols Dividend History
Learning Layer
Related Guides
Build conviction on EOLS by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.